CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension) Online Quantitative Aortographic Assessment of Aortic Regurgitation After TAVR: Results of the OVAL Study Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes Noninvasive Nuclear SPECT Myocardial Blood Flow Quantitation to Guide Management for Coronary Artery Disease Third-Generation Balloon and Self-Expandable Valves for Aortic Stenosis in Large and Extra-Large Aortic Annuli From the TAVR-LARGE Registry Intravascular ultrasound-guided drug-eluting stent implantation: An updated meta-analysis of randomized control trials and observational studies High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement Relation between baseline plaque features and subsequent coronary artery remodeling determined by optical coherence tomography and intravascular ultrasound
|<<... 99 100 101 102 103 104 105 ...>>|

Clinical Trial2021 Feb 16;143(7):673-684.

JOURNAL：Circulation. Article Link

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

TA Zelniker, M Ardissino, F Andreotti et al. Keywords: AF; AMI with atrial fibrillation and CHADS2 score ≥2; higher-dose edoxaban vs.lower-dose edoxaban regimen; warfarin; gender difference

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top